DelveInsight’s “Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Non-Radiographic Axial Spondyloarthritis (nr-AxSpA), historical and forecasted epidemiology as well as the Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Non-radiographic Axial Spondyloarthritis market report provides current treatment practices, emerging drugs, Non-radiographic Axial Spondyloarthritis market share of the individual therapies, and current and forecasted Non-radiographic Axial Spondyloarthritis market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Non-radiographic Axial Spondyloarthritis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Non-radiographic Axial Spondyloarthritis market.
Non-radiographic Axial Spondyloarthritis Overview
Non-radiographic axial Spondyloarthritis (Nr-AxSpA) belongs to the axial spondyloarthritis (axSpA) family of inflammatory conditions. These conditions affect the spine and SI joints, but signs and symptoms can occur in other parts of the body. Non-radiographic axial spondyloarthritis (Nr-AxSpA) is a type of arthritis in the spine. It causes inflammation, which leads to symptoms like redness, swelling, heat, stiffness, and pain. Nr-axSpA is a long-term inflammatory disease. In this disease, the immune system turns on itself and attacks healthy tissue in the joints.
Non-radiographic Axial Spondyloarthritis Epidemiology Insights
-
In 2021, the total prevalent cases of Nr-AxSpA were ~1,700,000 in the 7MM. These cases are anticipated to increase during the forecast period [2022–2032].
-
On the basis of gene-specific diagnosed prevalence of Nr-AxSpA, HLA-B27 accounted ~74% of cases in Germany, whereas, ERAP 1, IL-12, IL-17, and IL-23 accounted for ~26% of the cases.
-
The total diagnosed cases of Nr-AxSpA were ~850,000 in the 7MM in 2021. These cases are anticipated to increase during the forecast period [2022–2032].
-
Among EU4 countries, France accounted for the least number of total diagnosed prevalent cases of Nr-AxSpA , which were ~54,000 in 2021
Click here to learn more about the Non-radiographic Axial Spondyloarthritis Market Landscape
The Report Covers the Non-radiographic Axial Spondyloarthritis Epidemiology Segmented by:
-
Non-radiographic Axial Spondyloarthritis total prevalent cases
-
Non-radiographic Axial Spondyloarthritis total diagnosed cases
-
Non-radiographic Axial Spondyloarthritis gender-specific diagnosed prevelant cases
-
Non-radiographic Axial Spondyloarthritis gene-specific diagnosed prevalent cases
Non-radiographic Axial Spondyloarthritis Market Outlook
The Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) market trends by analyzing the impact of current Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of the Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Companies Working in the Non-radiographic Axial Spondyloarthritis Market
-
UCB Biopharmaceuticals
-
Novartis
-
Pfizer
-
Gilead Sciences
-
Eilly Lilly
And many others
Non-radiographic Axial Spondyloarthritis Therapies Covered and Analyzed in the Report:
-
Bimekizumab
-
Ixekizumab
-
Adalimumab
-
Secukinumab
And many others
Learn more about the Key Companies and Emerging Therapies in the Non-radiographic Axial Spondyloarthritis Market
Table of Contents
-
Key Insights
-
Non-radiographic Axial Spondyloarthritis Introduction
-
Executive Summary of Non-radiographic Axial Spondyloarthritis
-
Disease Background and Overview
-
Epidemiology and patient population
-
Non-radiographic Axial Spondyloarthritis Emerging Therapies
-
Non-radiographic Axial Spondyloarthritis Market Outlook
-
Market Access and Reimbursement of Therapies
-
Market Drivers
-
Market Barriers
-
Appendix
-
Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
Learn about the detailed offerings of the report @ Non-radiographic Axial Spondyloarthritis Market Outlook
Trending Reports by DelveInsight
-
Adalimumab Biosimilar Market
-
Arbovirus Infection Market
-
Artificial Pancreas Device System Market
-
Dental Equipment Market
-
Gluten Sensitivity Market
-
Hypothyroidism Market
-
Inflammatory Bowel Disease Market
-
Mayus Kinase Jak Inhibitors Market
-
Mild Dry Eye Market
-
Mucopolysaccharidosis Market
-
Oncolytic Virus Cancer Therapy Market
-
Pyoderma Gangrenosum Market
-
Transdermal Drug Delivery Devices Market
-
Intrathecal Pumps Market
-
Hedgehog Pathway Inhibitors Market
-
Yellow Fever Market
-
Laryngeal Cancer Market
-
Female Infertility Market
-
Gender Dysphoria Market
-
Chronic Brain Damage Market
-
Spain Healthcare Outlook Market
-
Malignant Fibrous Histiocytoma Market
Related Reports
Non-radiographic Axial Spondyloarthritis Pipeline Insights
“Non-radiographic Axial Spondyloarthritis – Pipeline Insight, 2023” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Non-radiographic Axial Spondyloarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by stage, route of administration, and molecule type.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services